Oppenheimer Trims Gilead Sciences (NASDAQ:GILD) Target Price to $105.00

Gilead Sciences (NASDAQ:GILDGet Free Report) had its target price reduced by investment analysts at Oppenheimer from $115.00 to $105.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price indicates a potential upside of 42.86% from the company’s previous close.

A number of other research firms have also recently commented on GILD. Deutsche Bank Aktiengesellschaft began coverage on Gilead Sciences in a research report on Thursday, November 9th. They issued a “hold” rating and a $75.00 price objective for the company. Barclays lifted their price target on Gilead Sciences from $82.00 to $85.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 23rd. UBS Group lowered their price objective on Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 8th. Royal Bank of Canada decreased their price target on Gilead Sciences from $78.00 to $76.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 7th. Finally, Wells Fargo & Company decreased their price target on Gilead Sciences from $90.00 to $84.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $87.71.

View Our Latest Analysis on Gilead Sciences

Gilead Sciences Stock Down 0.2 %

Gilead Sciences stock opened at $73.50 on Monday. The firm has a market cap of $91.58 billion, a price-to-earnings ratio of 16.33, a price-to-earnings-growth ratio of 0.96 and a beta of 0.20. Gilead Sciences has a 52 week low of $72.81 and a 52 week high of $87.86. The business’s 50-day moving average price is $80.74 and its 200 day moving average price is $78.21. The company has a quick ratio of 1.16, a current ratio of 1.46 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm’s revenue was down 3.7% on a year-over-year basis. During the same period last year, the business earned $1.67 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences will post 7.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares in the company, valued at approximately $8,709,586.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares in the company, valued at approximately $8,709,586.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 8,242 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total value of $702,465.66. Following the completion of the sale, the insider now directly owns 82,729 shares of the company’s stock, valued at $7,050,992.67. The disclosure for this sale can be found here. 0.21% of the stock is owned by company insiders.

Institutional Trading of Gilead Sciences

A number of large investors have recently made changes to their positions in the company. Capital World Investors raised its stake in shares of Gilead Sciences by 5.8% during the 2nd quarter. Capital World Investors now owns 80,929,316 shares of the biopharmaceutical company’s stock worth $6,237,075,000 after buying an additional 4,429,076 shares in the last quarter. State Street Corp increased its position in Gilead Sciences by 2.6% during the second quarter. State Street Corp now owns 59,317,162 shares of the biopharmaceutical company’s stock worth $4,571,574,000 after buying an additional 1,514,894 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Gilead Sciences by 1.9% during the second quarter. Geode Capital Management LLC now owns 24,212,636 shares of the biopharmaceutical company’s stock worth $1,861,363,000 after purchasing an additional 447,585 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Gilead Sciences by 324.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Gilead Sciences by 2.6% during the second quarter. Bank of New York Mellon Corp now owns 17,452,922 shares of the biopharmaceutical company’s stock worth $1,345,097,000 after purchasing an additional 440,718 shares during the last quarter. 82.33% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Recommended Stories

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.